Genable Technologies' Acquisition

Genable Technologies was acquired by Spark Therapeutics on March 07, 2016.

Genable utilizes well-established, clinically safe and effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene …

Articles about Genable Technologies' Acquisition: